Nektar Therapeutics Reports Q1 Loss Amid Key Developments

Introduction

Nektar Therapeutics (NASDAQ: NKTR) is a biopharmaceutical company headquartered in San Francisco, California. The company focuses on discovering and developing therapies that selectively modulate the immune system to treat autoimmune disorders, chronic inflammatory conditions, and cancer. As of June 24, 2025, NKTR shares traded on the Nasdaq at $20.90—an increase of 119.08% on the day—with a trading volume of 2,005,437 shares.

Corporate Structure

Founded in 1990, Nektar Therapeutics employs between 501 and 1,000 people across its global locations. Its primary research and development hub is located at 455 Mission Bay Boulevard South in San Francisco, with additional facilities in Huntsville, Alabama, and Hyderabad, India. The company utilizes a proprietary chemistry platform to advance multiple candidates through preclinical and clinical development and maintains co-development collaborations with industry partners.

Developments and News

On May 8, 2025, Nektar reported its first-quarter financial results for the period ending March 31, 2025:

• Cash and marketable securities totaled $220.7 million, a decrease from $269.1 million at December 31, 2024, which is expected to support operations into the fourth quarter of 2026.
• Revenue was $10.5 million, down from $21.6 million year-over-year, primarily due to the sale of its Huntsville manufacturing facility.
• Operating expenses were reported at $55.0 million compared with $57.1 million in the prior year; R&D expenses increased to $30.5 million, while G&A expenses rose to $24.3 million.
• The net loss was $50.9 million ($0.24 per share), or $46.4 million ($0.22 per share) on a non-GAAP basis, which excludes a $4.5 million non-cash loss from an equity-method investment.

Clinical and regulatory milestones include:

• In February 2025, the FDA granted Fast Track designation to rezpegaldesleukin (REZPEG) for the treatment of moderate-to-severe atopic dermatitis.
• In February, target enrollment was achieved in the REZOLVE-AA Phase 2b trial of REZPEG in patients with severe-to-very-severe alopecia areata, with topline data expected in December 2025.
• A Phase 2 study of REZPEG in atopic dermatitis (REZOLVE-AD) is set to report topline data from the 16-week induction period on June 24, 2025.
• The European Hematological Association Congress (June 12–15, 2025) will feature an oral presentation on NKTR-255 plus lisocabtagene maraleucel in relapsed/refractory large B-cell lymphoma.
• IND-enabling work for NKTR-0165, an anti-TNFR2 antibody, is on track for submission by the end of 2025, and the bispecific candidate NKTR-0166 is advancing into preclinical studies.

Financial and Strategic Aspects

Nektar’s financial position reflects a cash runway extending into late 2026, supported by $220.7 million in cash and marketable securities. The company’s Q1 2025 net loss widened compared to Q1 2024, mainly due to increased R&D and G&A expenses as it progresses key pipeline candidates. With no product sales following the divestiture of the Huntsville facility, revenue primarily consists of collaboration and licensing income.

Strategically, Nektar’s pipeline encompasses treatments for autoimmune diseases, hematological cancers, and solid tumors. Key collaborations involve CAR-T combinations in large B-cell lymphoma and partnerships in immunotherapy for bladder and lung cancers. Anticipated data readouts for REZPEG in atopic dermatitis and alopecia areata, along with upcoming IND filings, will be significant for the company’s valuation and strategic outlook.

Market Position and Industry Context

Operating within the biotechnology sector, Nektar competes with other companies developing immune-modulating therapies. Its price-to-sales ratio is approximately 1.36, with a market capitalization near $105.6 million, reflecting the market's assessment of its pipeline potential relative to current cash burn and profitability metrics. The focus on developing first-in-class and best-in-class therapies for larger patient populations aligns with industry trends towards targeted immunotherapies.

tl;dr

Nektar Therapeutics is scheduled to announce topline data for its REZOLVE-AD Phase 2b trial on June 24, 2025. In Q1 2025, the company reported a net loss of $50.9 million and held $220.7 million in cash, which is expected to fund operations into Q4 2026. The receipt of FDA Fast Track status for REZPEG in atopic dermatitis and the completion of enrollment in the REZOLVE-AA trial position the company for future important data readouts in December 2025. IND filings for NKTR-0165 and preclinical advancement of NKTR-0166 will influence the company’s near-term development strategy.